Pregled bibliografske jedinice broj: 843873
PCSK9 inhibitors - past, present and future
PCSK9 inhibitors - past, present and future // Expert opinion on drug metabolism & toxicology, 11 (2015), 10; 1517-1521 doi:10.1517/17425255.2015.1075506 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 843873 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
PCSK9 inhibitors - past, present and future
Autori
Reiner, Željko
Izvornik
Expert opinion on drug metabolism & toxicology (1742-5255) 11
(2015), 10;
1517-1521
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
alirocumab ; bococizumab ; cardiovascular disease prevention ; evolucumab
Sažetak
Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular disease (CVD) morbidity and mortality. Statins are the treatment of choice for lowering LDL-C but a considerable number of patients treated with statins are unable to achieve LDL-C target and many are statin-intolerant.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
108-1080134-0121 - Percepcija i prevencija čimbenika rizika za aterosklerozu u Hrvatskoj (Reiner, Željko, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Željko Reiner
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
